Progranulin expression correlates with dense‐core amyloid plaque burden in Alzheimer disease mouse models
- 21 May 2009
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 219 (2) , 173-181
- https://doi.org/10.1002/path.2580
Abstract
Amyloid‐β (Aβ) plaques are pathological hallmarks of Alzheimer disease (AD). In addition, innate inflammatory responses, such as those mediated by microglia, are integral to the pathogenesis of AD. Interestingly, only dense‐core plaques and not diffuse plaques are associated with neuritic and inflammatory pathology in AD patients as well as in mouse AD models. However, the precise neuropathological changes that occur in the brain in response to amyloid deposition are largely unknown. To study the molecular mechanism(s) responsible for Aβ‐mediated neuropathology, we performed a gene expression analysis on laser‐microdissected brain tissue of Tg2576 and APPPS1 mice that are characterized by different types of amyloid plaques and genetic backgrounds. Data were validated by image and biochemical analyses on different ages of Tg2576, APPPS1, and Aβ42‐depositing BRI‐Aβ42 mice. Consistent with an important role of inflammatory responses in AD, we identified progranulin (mouse Grn; human GRN) as one of the top ten up‐regulated molecules in Tg2576 (≈8‐fold increased) and APPPS1 (≈2‐fold increased) mice compared to littermate controls, and among the eight significantly up‐regulated molecules common to both mouse models. In addition, Grn levels correlated significantly with amyloid load, especially the dense‐core plaque pathology (p < 0.001). We further showed that Grn is up‐regulated in microglia and neurons and neurites around dense‐core plaques, but not in astrocytes or oligodendrocytes, as has been shown in AD patients. Our data therefore support the ongoing use of these mouse models in drug trials, especially those with anti‐inflammatory compounds. Moreover, the correlation of Grn with increasing disease severity in AD mouse models prompts human studies exploring the viability of GRN as a disease biomarker. Because loss of GRN has recently been shown to cause frontotemporal dementia and serves as a risk factor for AD, the strong GRN reactivity around dense‐core plaques is consistent with an important role of this factor in AD pathogenesis. Copyright © 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.Keywords
This publication has 45 references indexed in Scilit:
- Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family membersBrain, 2009
- Cell cycle re-entry mediated neurodegeneration and its treatment role in the pathogenesis of Alzheimer's diseaseNeurochemistry International, 2008
- The Inflammatory Response in Alzheimer's DiseaseThe Journal of Periodontology, 2008
- Gene expression study on peripheral blood identifies progranulin mutationsAnnals of Neurology, 2008
- Loss of progranulin function in frontotemporal lobar degenerationTrends in Genetics, 2008
- Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survivalThe Journal of cell biology, 2008
- Cerebral amyloid angiopathy: pathogenetic mechanisms and link to dense amyloid plaquesGenes, Brain and Behavior, 2008
- Aβ42‐driven cerebral amyloidosis in transgenic mice reveals early and robust pathologyEMBO Reports, 2006
- Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17Nature, 2006
- Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray ExperimentsStatistical Applications in Genetics and Molecular Biology, 2004